Novan Receives Verbal Guidance from FDA for SB206 and Announces Sato Program Advancement

The purpose of the meeting was to seek FDA feedback on the proposal to conduct one additional, well-controlled confirmatory study of SB206 to support a future New Drug Application (NDA).